Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare

Myricetin [529-44-2]

Stampa

Cat# HY-15097-1ml

Size : 10mM/1mL

Contatta il distributore locale :

Telefono : +1 850 650 7790

Marca : MedChemExpress

Richiedere ulteriori informazioni

Contatta il distributore locale :

Telefono : +1 850 650 7790

Description

Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	14.8 mg/mL Compound: 23	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 15568778]
BV-2	IC₅₀	> 100 μM Compound: 2	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction	[PMID: 27623545]
CWR22R	IC₅₀	13.1 μM Compound: 13	Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer	[PMID: 22789812]
H9	EC₅₀	35 μM Compound: 16	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	69 μM Compound: 16	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
HCT-116	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HCT-116	IC₅₀	23 μM Compound: 3	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	24 μM Compound: 3	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	28.2 μM Compound: 206b	Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay Cytotoxicity against human HCT116 cells assessed as reduction in cell growth by WST-1 assay	[PMID: 30917303]
HCT-116	IC₅₀	4.1 μM Compound: 3	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay	[PMID: 22212721]
HEK293	IC₅₀	> 10 μM Compound: 23	Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay	[PMID: 30943030]
HepG2	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HK-2	IC₅₀	> 20 μM Compound: Myricetin	Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HK2 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HT-29	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
HT-29	IC₅₀	2.12 μM Compound: Myricetin	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
HT-29	EC₅₀	3.02 μM Compound: Myricetin	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
Huh-7	CC₅₀	> 50 μM Compound: 28	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	46.9 μM Compound: 28	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Jurkat	IC₅₀	10 μM Compound: Myricetin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	12 μM Compound: Myricetin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
L02	IC₅₀	> 20 μM Compound: Myricetin	Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
L929	EC₅₀	55 μM Compound: myricetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	[PMID: 9287415]
L929	EC₅₀	59 μM Compound: myricetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	[PMID: 9287415]
MCF7	IC₅₀	> 20 μM Compound: Myricetin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32886510]
MCF7	IC₅₀	4.7 mg/mL Compound: 23	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 15568778]
MV4-11	GI₅₀	> 50 μM Compound: 7	Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
Peritoneal macrophage	IC₅₀	99 μM Compound: kp22	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
RS4-11	GI₅₀	> 50 μM Compound: 7	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
SK-BR-3	IC₅₀	> 100 μM Compound: 4	Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis Induction of apoptosis in human SKBR3 cells assessed as PARP cleavage by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	> 100 μM Compound: 4	Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis Inhibition of Hsp70 in human SKBR3 cells assessed as RAF1 protein degradation by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	> 100 μM Compound: 4	Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis Inhibition of Hsp70 in human SKBR3 cells assessed as HER2 protein degradation by Western blotting analysis	[PMID: 24548207]
SK-BR-3	IC₅₀	13.5 μM Compound: 4	Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay Displacement of GM-cy3B from Hsp90 in human SKBR3 cells after 24 hrs by fluorescence polarization assay	[PMID: 24548207]
U2OS	EC₅₀	14.7 μM Compound: Myricetin	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]

In Vitro

Myricetin exhibits the scavenging activity towards a number of radicals and ions. It displays poor activity (IC₅₀ value=1.4 mg/mL) in a superoxide dismutase (SOD)-like activity assay^[1]. It prevents cancer cell death via apoptosis via regulation of PI3K/Akt and MAPK signalling pathways^[2].
Myricetin exhibits antiphotoaging effects by quenching causative free radicals in the skin. Myricetin is able to suppress UVB-induced COX-2 expression in mouse skin epidermal JB6 P+ cells. It inhibits UVB-induced initiation of activator protein-1 and NF-κβ, as well as Fyn kinase activity^[1].
Myricetin inhibits viability of SKOV3 ovarian cancer cells in a dose-dependent manner. It induces DNA DSBs and ER stress, which leads to apoptosis in SKOV3 cells^[3].
Myricetin inhibits human Hsp70 by more than 80% with IC₅₀ values of 83, 11 and 12 μM, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Treatment of orthotopic pancreatic tumors with myricetin results in tumor regression and decreases metastatic spread^[2]. Exposure to 150 μM myricetin causes 14%, 26%, 5% and 49% inhibition of rabbit platelet aggregation, induced by ADP, arachidonic acid, collagen and PAF, respectively^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Masse moléculaire

318.24

Formule

C₁₅H₁₀O₈

CAS No.

529-44-2

Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=CC(O)=C(C(C(O)=C(C2=CC(O)=C(O)C(O)=C2)O3)=O)C3=C1

Structure Classification

Initial Source

Microorganisms

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvant et solubilité

In Vitro:

DMSO : ≥ 31 mg/mL (97.41 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 28.57 mg/mL (89.78 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1423 mL	15.7114 mL	31.4228 mL
5 mM	0.6285 mL	3.1423 mL	6.2846 mL
10 mM	0.3142 mL	1.5711 mL	3.1423 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

Pureté et documentation

Purity: 98.42%

Fiche technique (281 KB) SDS (393 KB)

COA (250 KB) RP-HPLC (208 KB) LCMS (94 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Semwal DK, et al. Myricetin: A Dietary Molecule with Diverse Biological Activities. Nutrients. 2016 Feb 16;8(2):90. [Content Brief]

[2]. Phillips PA, et al. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of thephosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011 Sep 28;308(2):181-8. [Content Brief]

[3]. Xu Y, et al. Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells. Mol Med Rep. 2016 Mar;13(3):2094-100. [Content Brief]

[4]. Jinwal UK, et al. Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. J Neurosci. 2009 Sep 30;29(39):12079-88. [Content Brief]

[5]. Tzeng SH, et al. Inhibition of platelet aggregation by some flavonoids. Thromb Res. 1991 Oct 1;64(1):91-100. [Content Brief]

Si può anche essere interessati nei seguenti prodotti:

Cat#

Descrizione

Cond.

Priced

HY-13653-50mg

(-)-Epigallocatechin Gallate [989-51-5]

50mg

HY-14590-100mg

Kaempferol [520-18-3]

100mg

HY-14590-50mg

Kaempferol [520-18-3]

50mg

Myricetin [529-44-2]

Cat# HY-15097-1ml

Contatta il distributore locale :

Marca : MedChemExpress

Contatta il distributore locale :

Myricetin Related Antibodies

Si può anche essere interessati nei seguenti prodotti: